Details

Autor(en) / Beteiligte

• Maio, Mariano
• Barros, Joaquina
• Joly, Marine
• Vahlas, Zoi
• Marín Franco, José Luis
• Genoula, Melanie
• Monard, Sarah C
• Vecchione, María Belén
• Fuentes, Federico
• Gonzalez Polo, Virginia
• Quiroga, María Florencia
• Vermeulen, Mónica
• Vu Manh, Thien-Phong
• Argüello, Rafael J
• Inwentarz, Sandra
• Musella, Rosa
• Ciallella, Lorena
• González Montaner, Pablo
• Palmero, Domingo
• Lugo Villarino, Geanncarlo
• Sasiain, María del Carmen
• Neyrolles, Olivier
• Vérollet, Christel
• Balboa, Luciana

Titel

Elevated glycolytic metabolism of monocytes limits the generation of HIF1A-driven migratory dendritic cells in tuberculosis

Ist Teil von

• eLife, 2024-06, Vol.12

Erscheinungsjahr

2024

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• During tuberculosis (TB), migration of dendritic cells (DCs) from the site of infection to the draining lymph nodes is known to be impaired, hindering the rapid development of protective T-cell-mediated immunity. However, the mechanisms involved in the delayed migration of DCs during TB are still poorly defined. Here, we found that infection of DCs with Mycobacterium tuberculosis (Mtb) triggers HIF1A-mediated aerobic glycolysis in a TLR2-dependent manner, and that this metabolic profile is essential for DC migration. In particular, the lactate dehydrogenase inhibitor oxamate and the HIF1A inhibitor PX-478 abrogated Mtb-induced DC migration in vitro to the lymphoid tissue-specific chemokine CCL21, and in vivo to lymph nodes in mice. Strikingly, we found that although monocytes from TB patients are inherently biased toward glycolysis metabolism, they differentiate into poorly glycolytic and poorly migratory DCs compared with healthy subjects. Taken together, these data suggest that because of their preexisting glycolytic state, circulating monocytes from TB patients are refractory to differentiation into migratory DCs, which may explain the delayed migration of these cells during the disease and opens avenues for host-directed therapies for TB.